^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:nesuparib (JPI-547) (PARP inhibitor, TNKS inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    4496 / 21 - JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction

    Published date:
    03/15/2023
    Excerpt:
    JPI-547 shows promising, preclinical antitumor effects against PDAC cells with HRD...